The Regulatory Intelligence Landscape in 2026

Regulatory intelligence, as the Drug Information Association defines it, is the act of gathering and analyzing publicly available regulatory information, communicating the implications, and monitoring the current regulatory environment for opportunities to shape future regulation.2 That definition has held for two decades. What has changed is the volume of information, the number of jurisdictions, and the expectation that the RI function delivers strategic input rather than back-office summaries.

The tooling landscape has split into four rough camps. First, the incumbent expert-curated platforms with expanding AI overlays. Second, the RIM-adjacent quality suites that treat RI as a compliance feed. Third, the medical-device-first platforms that never attempted pharma. Fourth, the in-house and startup builds that lean heavily on general-purpose LLMs. Each camp solves a different problem, and each has a different failure mode when leaders assume it solves all of them.

EXPERT-CURATED + AI

Cortellis Regulatory Intelligence

Clarivate’s platform covers 80+ global markets with 30+ years of curated regulatory expertise and more than 300,000 regulatory reports. The AI Regulatory Assistant is layered onto the curated corpus.3

RIMS + INTELLIGENCE

Freyr Solutions (RIMS + Freya)

Freyr pairs global registration management with Freya, an AI advisor that pulls insights from more than 200 regulatory agencies and is typically deployed alongside Freyr’s outsourced RA services.4

MEDTECH-ONLY

Rimsys Intel

Rimsys built exclusively for medical devices and diagnostics. Its 2025 AI Agents automate device-specific workflows, and its free intelligence hub is a useful cross-vendor reference for regulation tracking.5

QMS + AI OVERLAY

TrackWise Digital

Sparta Systems’ TrackWise Digital positions RI as one input to a broader QMS with auto-summarization and auto-categorization; it is the industry’s first QMS to layer AI onto quality decisions.6

UNIFIED RIM

Veeva Vault RIM

Veeva is not primarily an RI platform, but its unified RIM suite is where automated RI feeds typically land as work items. More than 200 companies have adopted Vault RIM across registrations, submissions, publishing, and archive.7

IN-HOUSE + LLM

Custom Scrapers and Agentic Builds

Many mid-cap teams have built ad-hoc scrapers plus LLM summarization over FDA, EMA, and MHRA feeds. Agentic RI frameworks are emerging that automate horizon scanning, natural language understanding, and risk assessment.8

The most important thing to understand about this map is that no vendor solves the whole problem. Cortellis and Freyr are strongest on curated intelligence and cross-market coverage but weaker on tight integration with your submission workflow. Veeva’s Vault RIM is the strongest on submission workflow but relies on external intelligence feeds. Rimsys is deep on devices but does not extend to pharma. TrackWise Digital treats RI as a downstream input to quality, which fits some operating models and misaligns with others. Custom LLM builds move fast, but production deployments frequently underestimate the validation and lifecycle costs that follow.

A second dynamic is worth naming. The category is being repriced. Commercial platform licenses that were routinely six-figure line items five years ago are now moving into seven-figure territory for global pharma coverage, which is one of the reasons build conversations are back on the table. At the same time, the marginal cost of a starter in-house build has collapsed. A regulatory affairs team with a decent developer can wire up FDA, EMA, MHRA, and PMDA scrapers, feed them into a general-purpose LLM for summarization, and have something running in six weeks. The question is not whether that starter build works. It usually does, for a while. The question is what happens when it needs to be validated, monitored, extended to a fifteenth market, and defended in an inspection. That is where the total cost of ownership numbers stop favoring build and start favoring buy, and where most starter builds discover they were undercapitalized from the outset.17

A third dynamic is that the operating environment for these tools is changing under them. FDA has been issuing more AI-related guidance than at any prior point in its history, EMA’s Annex 22 work is moving from draft toward implementation expectation, MHRA is running its own AI airlock program, and the EU AI Act has changed the definition of “high risk” for AI systems used in pharmaceutical decision-making. Every one of these developments changes what a good RI platform should be capable of surfacing, interpreting, and routing. The platforms are moving. The regulations they monitor are also moving. Any evaluation that treats a snapshot of vendor capability as a durable answer is going to be wrong within a year.18

The category problem. Buyers routinely conflate three distinct workflows: horizon scanning (spotting new guidance), intelligence synthesis (interpreting it), and RIM execution (acting on it inside your submission and change control processes). Most tools do one of the three well and market as if they do all three.

What Automation Actually Does Well

Where automation has moved from novel to reliable, the pattern is consistent. It is at its strongest when the task is high-volume, structurally repetitive, and tolerant of a false-positive rate that a human reviewer can filter downstream. Four use cases meet that bar today.

1. Bulk monitoring of guidance publications

Modern LLMs and specialized RI platforms can continuously scan agency websites, RSS feeds, and press channels, flagging new guidance documents from the FDA, EMA, MHRA, PMDA, and dozens of national authorities in near real-time.9 This is a task that used to consume a meaningful chunk of a senior regulatory affairs professional’s week and now runs unattended. The FDA’s CDRH alone is on track to publish or finalize more than a dozen priority guidance documents in FY 2026, and the pipeline of AI, real-world evidence, 510(k), and quality-system-related guidance is a moving target that no human can watch alone.10

2. Translation at scale

Multilingual LLMs and mature translation pipelines now handle the first-pass conversion of foreign-language guidance and regulatory bulletins into working English at a quality level that was aspirational three years ago. This does not remove the need for certified human translation of any material bound for a submission, but it is a real capability shift for horizon scanning across NMPA, ANVISA, TGA, and other non-English authorities.11

3. Keyword and relevance filtering

Once a stream of new guidance is captured, automation is good at pre-filtering by product class, therapeutic area, submission type, and named topic. This is where LLM-based classification meaningfully beats keyword lists, because it handles synonyms and adjacent terminology. A team that used to triage a hundred items to find the ten that matter now triages fifteen. That is a durable productivity gain.

4. Initial deduplication and consolidation

When the same guidance is picked up by three trade publications, referenced in a MHRA bulletin, and cross-listed on ICH’s website, automation collapses those into one item with the underlying primary source flagged. That is neither glamorous nor difficult, but it saves hours of low-value work per week per analyst.

5. Structured extraction from long documents

LLMs are increasingly reliable at extracting structured fields from long regulatory documents: effective dates, scope of applicability, cross-references to other guidances, and product classes affected. The output still needs a human check, but the accuracy floor has risen enough that this is a legitimate productivity aid rather than an inspection risk. This capability is where the difference between a well-tuned commercial platform and a starter in-house build tends to be most visible, because the commercial platforms have been iterating on this specific task for two or three release cycles longer than most in-house teams.

190+ FDA guidance documents issued in a single recent fiscal year, driving the case for automated monitoring.1
300+ regulatory authorities that global RI functions may need to monitor concurrently.1
50% pharmacovigilance cost reduction target that IQVIA has publicly stated for its generative-AI-driven approach.12

The pattern that works. Bulk monitoring, translation, filtering, and deduplication all share the same shape: the cost of an error is a wasted human review, not a missed regulatory obligation. That asymmetry is what makes them safe to automate first.

Where Automation Consistently Falls Short

The failure modes are less discussed in vendor pitches but are the ones that matter most. In each case, the risk is not that the automation is inaccurate at the surface level. The risk is that it produces confident-sounding output that appears interpreted but has not actually engaged with what regulators mean.

Contextual interpretation

A new EMA reflection paper on AI in pharmacovigilance is not just a document. It is an artifact of an ongoing conversation with EFPIA, the CHMP, and national authorities, layered on top of the EU AI Act, GVP modules, and prior scientific advice. LLMs summarize the document. They do not know which paragraph was added under pressure from a specific stakeholder or which reference to a prior guidance is doing the real regulatory work. A senior regulatory affairs professional reading the same document sees a conversation. Automation sees text.

Novelty assessment

Deciding whether a piece of guidance is a genuine departure from precedent, a clarification of existing expectations, or a restatement of an old position dressed as new is what regulatory intelligence is for. This is a judgment call that requires memory of what the agency said in prior guidances, warning letters, and advisory committee minutes, and it requires context on how that agency’s reviewers have interpreted comparable language in real submissions. Current automation does not have this context. It flags the document as new. It rarely tells you whether it is important.

Cross-guidance synthesis

Real regulatory questions almost never map to a single guidance document. Answering “what are our AI validation obligations for the model we deploy in EU manufacturing?” pulls from EMA Annex 22 draft, EU GMP Chapter 4, EU AI Act high-risk provisions, GVP Module IX on signal management, and the applicable ICH quality guidances. Automation can retrieve each document. It cannot yet reliably synthesize how they interact in a specific operational context.13

Cross-market interpretation

The same underlying obligation is expressed differently by FDA, EMA, MHRA, PMDA, and NMPA, and the differences matter. Machine translation gets you the words. Regulatory judgment tells you that FDA’s expectation of “adequate justification” is not the same standard as EMA’s expectation of “sufficient scientific rationale,” even when the machine translation renders them identically. Cross-market interpretation is where in-house LLM builds get organizations into the most trouble, because the summaries feel authoritative and the differences are hidden in nuance.11

Precedent-weighted judgment

Any experienced regulatory professional will tell you that what a guidance says on paper is only part of the picture. What matters equally is how the reviewing division has actually interpreted comparable language in the last two years, which questions they have asked in Type C meetings, and which arguments have or have not landed in health-authority interactions. This is precedent-weighted judgment, and it lives in the heads of senior reviewers, in redacted meeting minutes, in industry association working groups, and in the informal exchanges between former agency staff and current industry practitioners. No automated system today has meaningful access to this layer. Automation summarizes the surface. Judgment operates below it. Treating the two as interchangeable is the most consequential category error we see in RI operations.

The Purolea pattern. The FDA warning letter to Purolea in 2025 was not, in our reading, an anti-AI decision. It was a decision against unvalidated automation being trusted to make regulated decisions. The failure mode was operating an automated system without an appropriate human decision record. The same pattern applies to RI automation used to shape strategy, respond to health authority questions, or drive submission planning.

Human-in-the-Loop Patterns That Actually Work

Regulators have been increasingly explicit that automated systems supporting GxP decisions must incorporate human oversight, real-world performance monitoring, and traceable decision-making.14 The FDA’s AI/ML Action Plan and its January 2025 draft guidance on AI in drug and biological product regulation both reinforce this, as does EMA’s Annex 22 work. What is less discussed is what the human-in-the-loop actually looks like in a functioning RI operation.

1

Automated ingestion, human triage

Automation ingests every candidate item, applies classification and deduplication, and produces a ranked queue. A human triages the queue at least daily. Nothing exits the queue without a human decision. This is where most mature operations sit today.

2

Automated first-pass summary, human authoring of the RI record

The tool drafts a summary. A human reviews, corrects, adds context, and is named as the author of the RI record. The human is on the hook for the interpretation, and the tool is a productivity aid. Attribution matters here because it changes the reviewer’s incentive.

3

Automated cross-reference retrieval, human synthesis

Retrieval-augmented tools pull the related prior guidances, warning letters, and precedents. A human does the synthesis of what these mean together for a specific product or submission question. This is the pattern that unlocks the most value for cross-guidance work without introducing the interpretation risks above.

4

Automated draft, senior reviewer accountability

For internal briefings, position papers, or health-authority-facing content, automation drafts a starting point. A named senior regulatory reviewer signs off. The signature carries the accountability. The signoff is captured in a way that would satisfy an inspector asking who made the decision.

5

Continuous performance monitoring

Where automation is embedded into a repeatable RI workflow, the performance of the automation is itself monitored: false negatives (missed guidances), false positives (irrelevant flags), quality of summaries versus human-corrected versions. The monitoring cadence is documented and reviewed at least quarterly.

The pattern that consistently fails is what we sometimes call “human-on-the-loop with the loop closed.” That is where the automation acts, the human is nominally responsible for oversight, but the oversight is neither scheduled nor structured, and no one is looking at output quality in aggregate. Organizations arrive at this state not by policy but by drift: an efficiency-minded team removes friction from the workflow until the human step becomes vestigial. Inspectors and auditors are increasingly attuned to this pattern.

The SD perspective. Human-in-the-loop is not a compliance ornament to add on top of automation. It is a design constraint that changes what the automation should be built to do in the first place. The best regulatory intelligence teams we work with treat automation as a set of drafting and retrieval tools for named human decision-makers, not as a system that produces answers. That distinction shows up in the tool choices, the workflow, the accountability model, and, ultimately, in whether the operation stands up under audit.

Vendor Selection Criteria That Matter

Most published vendor selection frameworks for regulatory intelligence software focus on feature checklists and pricing. That is a starting point but rarely predicts success. Six criteria matter more than the features that vendors demo.

Depth of curated intelligence versus generative summarization

Ask what proportion of the platform’s “intelligence” comes from human-curated analysis by regulatory professionals versus generative summaries of source documents. Curated intelligence is expensive and its scale is what drives price. Generative summaries are cheap and are what most vendors are quietly leaning on to fill gaps. Both have a place, but confusing them will produce misplaced trust in output. Cortellis and Freyr both invest heavily in curated content; some of the newer entrants are almost entirely generative.34

Coverage that matches your portfolio geography

Vendors advertise coverage of 80 to 200+ markets. What matters is whether the ten markets your portfolio depends on are covered with depth. Ask specifically about the last time the vendor’s team pushed a substantive update on your top three health authorities, and ask to see the last five items published for each. This is a five-minute test that separates real coverage from a market on a list.

Integration with your RIM and QMS

An RI feed that terminates in an email or a portal is a feed. An RI feed that automatically opens a work item in Veeva Vault RIM, TrackWise Digital, or your equivalent quality system with the source document attached and pre-filled classifications is a workflow. The second is meaningfully more valuable and meaningfully harder to configure. Ask specifically about connectors and how they handle authentication, audit trail, and change control.7

Traceability and audit trail

For any AI-generated output, the platform should provide unambiguous source citations, retention of the input document, and a versioned log of any prompt or model changes that would affect how the output was generated. This is not a nice-to-have. This is what makes the platform’s output usable in a GxP context.

Roadmap credibility and vendor lock-in

Regulatory intelligence platforms are being repriced and repositioned faster than in the last decade. Ask what percentage of the R&D budget is going into AI features versus curated content. Ask what the customer’s exit path looks like, including export of custom classifications, notes, and internal RI records. A vendor that cannot describe an exit path in operational terms is a vendor whose renewal negotiation will not go well.

Human expertise on the vendor side

Ask who the platform’s senior regulatory analysts are, where they came from, and whether they are still on staff. A platform’s intelligence value is capped by the depth of the humans on the vendor side who review, tag, and interpret content. This is uncomfortable diligence for procurement teams but is the single most predictive question we have seen.

Validation posture

For any RI output that will inform a GxP decision, the platform must be validatable in a way that fits your Computer System Validation (CSV) or Computer Software Assurance (CSA) framework. Ask the vendor for their validation package, their documented change-control procedure for model updates, and their communication protocol when the underlying LLM or classification model changes materially. A vendor that treats model changes as invisible product improvements is a vendor whose output cannot be relied on for validated use. This is the criterion most often skipped in procurement and most often revisited during the first inspection or audit that touches an RI-informed decision.

Pricing structure and TCO

Look past the headline license to the full TCO over a three-year horizon. Common hidden costs include per-user or per-market license expansion, connector fees for integration with Vault RIM or TrackWise Digital, professional services for onboarding, retraining fees when the vendor updates its model, and premium pricing for advanced analytics or custom feeds. A well-structured procurement finds these before signature. A poorly structured one finds them at renewal, when leverage has evaporated.

A Build-vs-Buy Decision Framework

The build-versus-buy question in regulatory intelligence is being asked more often, partly because LLM APIs make a starter build look deceptively cheap, and partly because commercial RI licenses have become a material line item for mid-cap organizations. The honest answer for most companies is a hybrid, but the shape of the hybrid depends on where you sit against three axes.15

Dimension Lean-to-buy signal Lean-to-build signal
Portfolio breadth Global portfolio across 30+ markets; multiple therapeutic areas Focused portfolio in 2 to 5 markets; single-modality specialization
Regulatory team size Fewer than 10 dedicated RI professionals; RI is a stretch role 15+ RI professionals with mature triage and analysis workflows
Engineering maturity No in-house ML operations capability; limited GxP validation experience with AI Mature MLOps team with prior GxP validation of AI systems in production
Integration surface Standard RIM (Veeva Vault or equivalent) with vendor connectors available Non-standard or heavily customized RIM and QMS with unique data model
Time to value Need production RI coverage in less than 6 months Can invest 12 to 18 months and accept iteration during that window
Strategic differentiation RI is a compliance-enabling function; parity with peers is fine RI is a competitive differentiator; earlier signal drives real strategic advantage

Where multiple dimensions lean the same direction, the decision is straightforward. Where they conflict, we consistently see three durable hybrid patterns.

The commercial-primary hybrid

A curated commercial platform such as Cortellis or Freyr as the primary source of truth, augmented by lightweight in-house automation for two or three high-priority feeds that the platform underweights (for example, a specific FDA advisory committee or an internal legal-team-driven flag on state AI legislation). Ninety percent of value from the vendor, ten percent from targeted in-house. This is the safest default for most mid-cap and large pharma.

The commercial-plus-agent hybrid

A commercial platform for horizon scanning and curated intelligence, with an internally built agentic layer that handles synthesis tasks: pulling relevant prior guidances, drafting cross-market comparisons for a named product, and preparing briefing materials. This pattern works when the internal team has real MLOps depth and is prepared to validate and monitor its own agentic system. It is the fastest-growing pattern among top-20 pharma.

The narrow-domain build

A pure in-house build limited to a narrow, well-defined domain: medical device regulation for a specific product family, a specific therapeutic area, a specific geographic region. This works when the organization’s expertise is very deep and the commercial platforms underserve the niche. It rarely scales beyond its original scope without becoming a project that would have been cheaper as a buy.

The trap. The single most common failure mode we see is teams that build a starter RI tool, deploy it into production without proper validation or lifecycle monitoring, watch it accumulate technical and regulatory debt, and eventually reach a point where they have neither the confidence to trust it nor the will to replace it. If you build, plan for the full lifecycle from day one, including model monitoring, drift detection, and a documented human review protocol. If you cannot commit to that plan, buy.

A Maturity Model for Regulatory Intelligence Operations

Most maturity models for RI describe capability in the abstract. We find leaders benefit more from a model that describes the operating characteristics they can observe today and use to identify their next investment. The five stages below are drawn from what we have seen work across pharma and biotech clients.16

STAGE 1

Reactive

RI is done by whoever notices something first. Coverage is inconsistent, records are ad hoc, no defined triage cadence, and no single owner. Common in small biotechs before the first health authority interaction of scale.

STAGE 2

Owned but manual

A named RI owner or hybrid RA/RI role, a defined watchlist of authorities, manual review, and a shared RI log in a document or spreadsheet. Coverage is stable but limited by that one person’s bandwidth.

STAGE 3

Automated ingestion

A commercial RI platform or internal automation handles horizon scanning and initial deduplication. Humans still do all interpretation. Records live in a searchable repository. Coverage expands significantly.

STAGE 4

Integrated intelligence

RI feeds are wired to RIM and QMS. Triaged items automatically open work items with source documents attached. Cross-guidance retrieval is automated as an aid. Named senior reviewers own interpretations. Performance of automation is monitored quarterly.

STAGE 5

Strategic RI

RI is a formal input to portfolio decisions, health authority engagement strategy, and lifecycle management. The team shapes regulation through comment letters and workshop participation. Automation is a productivity backbone; interpretation is the organizational competence.

TRAP

Pseudo-Stage 4

Appears to be Stage 4 but the human oversight has drifted. Work items open automatically, get closed automatically, and no one is systematically reviewing the automation’s decisions. This is the most audit-exposed state and is where the FDA and EMA are looking hardest.

The right maturity target for any organization is not Stage 5. It is the stage that matches portfolio complexity, regulatory footprint, and strategic ambition. A specialty pharma with three approved products in two markets often finds Stage 3 is the right endpoint. A top-20 pharma with a global commercial portfolio and an active development pipeline should be running at Stage 4 with elements of Stage 5 in specific therapeutic areas.

The transition points between stages are where investment decisions actually get made, and each transition has a characteristic failure mode. Moving from Stage 2 to Stage 3 is where teams first buy a commercial platform, and the failure mode is over-buying: procuring coverage of 80 markets when the portfolio only touches 10, then paying for capability that no one uses. Moving from Stage 3 to Stage 4 is where integration with RIM and QMS becomes the primary technical work, and the failure mode is under-scoping the integration project. It rarely costs less than the platform license. Moving from Stage 4 to Stage 5 is where the RI function shifts from operational to strategic, and the failure mode is the organizational one: the CEO or Chief Regulatory Officer keeps treating RI as compliance overhead, and the function never gets the strategic mandate that would justify the operating model.

A practical assessment approach we use with clients is to score each of five capability areas against the five stages: horizon scanning coverage, interpretation quality, integration with downstream systems, human accountability model, and strategic engagement with regulators. Most organizations discover they are at Stage 3 or Stage 4 in one or two areas and Stage 1 or Stage 2 in the others. That unevenness is where the next 12 months of investment should be pointed, and it is much more useful information than a single-number maturity score.

What good looks like. The RI operations we consider genuinely strong share four traits: they can produce a defensible audit trail for how any decision was reached; they have named human accountability for every interpretation; they measure the performance of their automation the way they measure any other GxP system; and they use RI as a strategic input rather than a compliance byproduct. None of that requires the biggest budget. It requires the right operating model.

Conclusion

Regulatory intelligence automation in 2026 is powerful, mature, and easy to over-trust. Bulk monitoring, translation, filtering, and deduplication have crossed the threshold from novel to reliable. Contextual interpretation, novelty assessment, cross-guidance synthesis, and cross-market translation have not. Teams that treat these categories differently, and design their operating model around the split, get real productivity without the audit exposure. Teams that let the marketing narrative shape their deployment end up with confident-looking output that has not actually engaged with what regulators mean. That is a strategic risk, not a tooling problem.

The leaders who navigate this well share a common posture. They resist the temptation to treat vendor demos as evidence of production readiness. They invest in the human accountability model before they invest in the automation. They validate their RI tooling the way they would validate any other system that touches a GxP decision. They monitor the automation’s performance in production, not just at go-live. And they hold the strategic question of what RI is for as a leadership conversation rather than a purchasing conversation. The organizations that do these things end up with regulatory intelligence functions that are meaningfully faster, more comprehensive, and more strategically useful than what they had five years ago, without giving up the interpretive rigor that regulators expect and inspectors verify.

Sakara Digital works with pharma and biotech organizations building regulatory intelligence operations that are automation-enabled without being automation-dependent, with the vendor mix, human-in-the-loop pattern, and maturity roadmap that fits their portfolio and their tolerance for regulatory risk. If you are evaluating an RI platform, considering an in-house build, or reworking your existing operation, and want an independent perspective on where automation actually earns its keep in your context, we are happy to have that conversation.